Giant Cell Tumor of Bone, from the CureRays guide library.

Giant cell tumor of bone is usually benign but locally aggressive, eating into bone near a joint; surgery cures most, and a targeted drug (denosumab) can shrink tumors that can't be removed.

What it is.

Giant cell tumor of bone (GCTB) is named for the large, many-nucleus cells seen under the microscope. It typically appears in young adults at the end of a long bone right next to a joint — most often the knee, wrist, or shoulder. It is classified as benign because it rarely spreads, yet it behaves aggressively in place, destroying bone and sometimes returning after treatment. A small fraction can spread to the lungs (usually slow-growing) or, very rarely, turn malignant. The tumor is driven by overactive bone-dissolving cells (osteoclasts) recruited by a signal called RANKL — the target of modern drug therapy.

How radiation treats it.

Radiation damages the DNA of dividing tumor cells so they can no longer multiply, and the tumor gradually stops growing and hardens. For giant cell tumor of bone, radiation is used cautiously and only when surgery and denosumab are not options, because irradiating a benign tumor carries a small long-term risk of malignant change. When it is needed, image-guided, tightly shaped radiation keeps the dose on the tumor and limits exposure to healthy bone. Treatment is painless and given in short daily sessions.

The ways we can treat it.

Denosumab (targeted antibody). Blocks RANKL, the signal that recruits bone-destroying osteoclasts, so the tumor stops eroding bone and often forms a firm shell. Used for spine/sacrum/pelvis tumors and to down-size before surgery.

Radiation therapy (selective, lower priority). Reserved for tumors that can't be removed and aren't controlled by denosumab — such as some spinal or sacral lesions — because radiation carries a small risk of turning the tumor malignant. Modern conformal techniques lower that risk.

Embolization. Blocking the tumor's blood supply through a catheter can control bleeding and shrink large pelvic or spinal tumors before surgery.

Questions we hear often.

Is this cancer? It is classified as benign — it almost never spreads — but it is locally aggressive and destroys bone, so it must be treated thoroughly. A small minority can spread to the lungs or rarely become malignant, which is why follow-up matters.

Will I lose my joint? Usually not. Most tumors are removed by extended curettage that preserves the joint. Only when too much bone is destroyed is the segment replaced with a graft or prosthesis.

Why is radiation used so carefully here? Because GCTB is benign and often affects young people, irradiating it carries a small long-term risk of turning it cancerous. So radiation is saved for tumors that can't be removed or controlled with denosumab, using precise modern techniques.

This guide is informational only. It is not medical advice — please confirm anything here with your care team.